SALV

TIDMSALV

RNS Number : 0548Z

SalvaRx Group plc

28 August 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Update re proposed disposal and demerger

Further to the announcement of 14 August 2018 relating to the proposed disposal of the Company's 94.2 per cent. interest in its subsidiary SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company has been informed that the Portage shareholder circular has now been submitted to the Canadian Securities Exchange ("CSE") for review. Following completion of the CSE review, both Portage and the Company will publish their respective shareholder circulars and a further announcement will be made by the Company.

Enquiries

 
 SalvaRx Group plc 
 Ian B. Walters, MD (Chief Executive)         Tel: +1 203 441 5451 
 Northland Capital Partners Limited           Tel: +44 (0) 20 3861 
  Nominated Adviser and Broker                                6625 
 Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
 Vadim Alexandre (Corporate Broking) 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDFMGZRVRNGRZM

(END) Dow Jones Newswires

August 28, 2018 12:40 ET (16:40 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Feb 2023 to Mar 2023

Salvarx (LSE:SALV)
Historical Stock Chart
From Mar 2022 to Mar 2023